| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4029878 | Ophthalmology | 2006 | 7 Pages |
Abstract
Ranibizumab appears to be a well-tolerated therapy for patients with DME. This pilot study demonstrates that ranibizumab therapy has the potential to maintain or improve BCVA and reduce retinal thickness in patients with center-involved clinically significant DME.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Dal W. MD, Jeffrey S. MD, Trexler M. MD, Jay S. MD, Joy M. RN, BSN,